Synmosa Biopharma Corporation (4114) Fair Value & Analysis
Healthcare · TW · Market cap 16.0B TWD
Fair value as of: Jul 23, 2026
From 26 valuation models · updated 17 days ago
Fair value updated Jul 23, 2026, revised from 26.83 TWD to 24.88 TWD (−7.3%) since Jul 9, 2026. Share price −3.2% over the past month.
Below-average quality, and screening another 15% overvalued on our models.
What matters now
- A fairly wide model range (13.93 TWD to 32.08 TWD) leaves room in how you read the outcome.
- Our model range runs from 13.93 TWD (bear) to 32.08 TWD (bull), base 24.88 TWD. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 41/100 (below-average quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.
How to read this chart
60‑month range 11.86 TWD – 142.73 TWD · fair‑value band 13.93 TWD – 32.08 TWD · the 29.25 TWD price screens above the 24.88 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 23, 2026.
Analysis
Synmosa Biopharma Corporation (4114) currently trades at 29.25 TWD, while our model-based Fair Value estimate is 24.88 TWD, implying the stock looks roughly 14.9% overvalued today. The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Synmosa Biopharma Corporation generated revenue of 6.4B TWD at a net margin of 12.7%. Revenue grew 12.5% year over year. It earns a return on equity of 6.2%. Net debt stands at 566M TWD. Fundamentals as of Jul 23, 2026
Our scenario range runs from 13.93 TWD (bear case) to 32.08 TWD (bull case); at 29.25 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 27% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -15%, 4114 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (31.74 TWD) versus Growth DCF (6.42 TWD). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 42 · Market factors (momentum, volatility) 36
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Synmosa Biopharma Corporation, a specialty pharmaceutical company, engages in the manufacturing and sales of various pharmaceuticals and medical devices in Taiwan, China, the United States, Canada, Thailand, Malaysia, Singapore, and internationally.
Full company description
Synmosa Biopharma Corporation, a specialty pharmaceutical company, engages in the manufacturing and sales of various pharmaceuticals and medical devices in Taiwan, China, the United States, Canada, Thailand, Malaysia, Singapore, and internationally. It offers medicines for urology, hormones, oncology, dermatology, cardiovascular, CNS, gastrointestinal, and other areas; and effervescent tables, granules, and nasal sprays. The company is also involved in provision of cosmetics, veterinary drugs, chemical food additives, and beverages; wholesale retail of environmental drugs; and import and export of related businesses. The company was founded in 1959 and is based in Taipei, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Synmosa Biopharma Corporation reported revenue of 6.2B TWD in FY2025 versus 3.2B TWD in FY2021, a compound +17.6%/yr. Reported net income was 822M TWD in FY2025, compounding +28.2%/yr from FY2021.
4114 screens 15% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 626 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Synmosa Biopharma Corporation with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Synmosa Biopharma Corporation (4114) overvalued or undervalued?
What is the fair value of 4114?
What is the quality score of 4114?
What is the revenue of Synmosa Biopharma Corporation (4114)?
What is the net profit margin of 4114?
Does Synmosa Biopharma Corporation pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Synmosa Biopharma Corporation and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.